Shane schaffer cingulate
WebShared by Shane Schaffer Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD BioSpace Liked by Shane … Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. …
Shane schaffer cingulate
Did you know?
WebWho is Cingulate Headquarters 1901 W 47th Pl, Kansas City, Kansas, 66205, United States Phone Number (913) 942-2300 Website www.cingulate.com Revenue $19.2M Stock … WebJan 16, 2024 · Cingulate Therapeutics chairman and CEO Shane Schaffer said: “Before Cingulate Therapeutics embarks on the studies necessary to gain FDA approval, we’ve been able to gain valuable insight as to how our assets are expected to perform in-vivo.
WebCingulate said the agreement spans cross-functional services via an omnichannel marketing approach aimed at successfully managing pre-commercial support during its phase 3 trials and to... WebShane J. Schaffer. Age : 48. Public asset : 1,520,297 USD. Linked companies : Cingulate Inc. Summary. Shane J. Schaffer founded Cingulate, Inc., Cingulate Works, Inc. and Cingulate …
Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed … WebCingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens …
WebFeb 8, 2024 · Cingulate Inc. today announced updates to its 2024 clinical program for its lead candidate CTx-1301, an investigational asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). ... and ultimately improving patient outcomes,” said Shane J. Schaffer, Cingulate Chairman and Chief Executive Officer. “These studies allow ...
WebFeb 15, 2024 · Cingulate Inc. today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2024, at 10:30 a.m. ET. ... Cingulate’s presentation will be available by request to Aegis for the duration of the conference, from February 23 through ... stereotactic biopsy thalamusWebShane Schaffer posted on LinkedIn Shane Schaffer’s Post Shane Schaffer 1y Cingulate Inc. 1,079 followers 1y Cingulate® Provides 2024 Clinical Plan for CTx-1301, an Investigational... pip myth busterWebShane Schaffer is from Kansas City, Kansas, United States. Shane is currently Chairman and CEO at Cingulate Inc., located in Mission, Kansas, United States. You can find Shane … stereotactic biopsy recovery timeWebApr 14, 2024 · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. … stereotactically injectedWebAug 18, 2024 · Shane Schaffer, the CEO of Cingulate Therapeutics, said this weekend’s meeting of the company’s seven-member scientific advisory board will include experts from the United States, Canada and... pip mr templateWeb20 hours ago · Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ... pip mysql installWebNov 1, 2024 · KANSAS CITY, Kan., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the completion of its study … pip nameerror: name pip is not defined